Kobo Biotech Ltd.
Bombay Stock ExchangeTotal Valuation
Kobo Biotech Ltd. carries a market capitalization of 201.08M, placing it among publicly traded companies globally. Its enterprise value stands at 90.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 201.08M |
| Enterprise Value | 90.26M |
Enterprise Valuation
| EV / Sales | N/A |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 90,256.60 |
Financial Position
Kobo Biotech Ltd. maintains a current ratio of 0.45, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -212.21, indicating conservative leverage, while an interest coverage ratio of -50,566.00 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.45 |
| Quick Ratio | 0.01 |
| Debt / Equity | -212.21 |
| Debt / EBITDA | N/A |
| Interest Coverage | -50,566.00 |
Stock Price Statistics
Kobo Biotech Ltd.'s stock has gained approximately 251.66667% over the past 52 weeks. The 50-day moving average sits at 4.72, while the 200-day moving average is 3.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | 251.66667% |
| 50-Day Moving Average | 4.72 |
| 200-Day Moving Average | 3.11 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -50.57M, while operating income came in at -50.57M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -50.57M |
| Pretax Income | -50.33M |
| Net Income | -50.33M |
| EBITDA | -50.57M |
| EBIT | -50.57M |
| Earnings Per Share (EPS) | -2.12 |
Scores
Kobo Biotech Ltd. posts an Altman Z-Score of -4.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.74 |